Dear Chairwoman DeLauro, Chairman Leahy, Ranking Member Granger, and Vice Chairman Shelby:

Thank you for your leadership in championing sustained, real growth in medical research funding. As Congress returns to session, the undersigned members of the Ad Hoc Group for Medical Research urge you to swiftly finalize a fiscal year (FY) 2023 spending package that prioritizes robust investments in agencies and programs that improve the nation’s health and well-being, including funding for the National Institutes of Health (NIH). The Ad Hoc Group for Medical Research is a coalition of patient and voluntary health groups, medical and scientific societies, academic and research organizations, and industry, dedicated to enhancing the federal investment in biomedical, behavioral, social, and population-based research supported by the NIH.

We greatly appreciate that both the House Appropriations Committee-passed (H.R. 8295) and Senate Majority (S. 4659) Labor-HHS-Education spending bills include strong increases for the NIH base in FY 2023, which would equip the nation to combat both known and unprecedented health threats, convert the hope of improved health and well-being into a reality for patients and their families, and more. Earlier this year, the Ad Hoc Group for Medical Research outlined the need for at least $49.1 billion for NIH’s base in FY 2023. To maximize the potential of tomorrow’s research discoveries to make rapid progress toward these goals, we urge you to provide at least the House Appropriations Committee-passed $47.5 billion for NIH’s base. Continuing the momentum of the prior seven years of bipartisan support for meaningful funding growth in the NIH’s existing institutes and centers is key to ensuring that the nation can continue to accelerate the development of breakthrough cures while supporting high quality jobs across the country, catalyzing new industries, and enhancing the U.S.’s global competitiveness.
Additionally, we appreciate that both bills ensure that the FY 2023 investment for the Advanced Research Projects Agency for Health (ARPA-H) supplements, rather than supplants, the NIH's base. While complementary, NIH and ARPA-H have distinct and important missions. The NIH is the nation's primary funder of medical research behind almost any test, treatment, or cure for patients; prioritizing strong investments in the NIH's foundational work will be critical to the success of ARPA-H, particularly as it builds its operational capacity as the inaugural director takes office.

Additionally, our organizations strongly support an approach to the final FY 2023 spending package that avoids additional continuing resolutions (CRs) past December. Aside from the budget implications, CRs create inefficiencies and add uncertainty. Avoiding further delays in finalizing funding for the current fiscal year will enable our nation's medical research enterprise to be maximally efficient and strategic in addressing myriad health needs in FY 2023. We strongly urge you to work swiftly in securing bipartisan, bicameral agreement on topline discretionary spending allocations and to ensure any final budget agreement reflects a strong commitment to the nation's health and the medical research and workforce that improve it.

Once again, we commend you for continuing to recognize the incomparable value of the federal investment in the NIH, and we look forward to working with you to secure, at a minimum, $47.5 billion for the agency's base budget, in addition to funding for ARPA-H, in FY 2023.

Sincerely,
XX Signatories as of DATE

cc:
The Honorable Nancy Pelosi, Speaker, U.S. House of Representatives
The Honorable Kevin McCarthy, Minority Leader, U.S. House of Representatives
The Honorable Charles Schumer, Majority Leader, U.S. Senate
The Honorable Mitch McConnell, Minority Leader, U.S. Senate